Naveen Pemmaraju, Professor in the Department of Leukemia at UT MD Anderson Cancer Center, shared a post X:
“Awesome to spend time with our world all-star MPN crew yesterday European Hematology Association for a very memorable, very powerful MPN oral session highlighting potential for Disease Modification as we enter, potentially, a new golden era of novel targeted therapy.”
Other articles about EHA 2026 on OncoDaily.
